Skip to main content
Caplight Logo









iCell Gene Therapeutics

iCell Gene Therapeutics

Private
Stony Brook, New YorkHealthcare & Life Scienceshttps://www.icellgene.com/

Last Round

Grant

Oct 8, 2020

Total Funding Raised

$3.1M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

iCell Gene Therapeutics is a biotechnology company that develops chimeric antigen receptor (CAR) immunotherapies for the treatment of autoimmune diseases and cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

CAR-T therapycell therapycompound CARcCARautoimmune disease treatmentcancer immunotherapyCAR-NKbiotechnologyclinical trialsdrug developmentnext-gen CARliving drugsprecision medicineviral vector manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

iCell Gene Therapeutics Comparables

Compare iCell Gene Therapeutics with similar companies based on industry and business-model similarity.

iCell Gene Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Luminary Therapeutics, Inc.
82%
AstraZeneca
81%
Lyell Immunopharma
77%

iCell Gene Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 8, 2020

Key People

Founding team and executive leadership

Timothy E. Morris

Chief Financial Officer

Executive Team

iCell Gene Therapeutics Investors

Notable investors and investment history

iCell Gene Therapeutics investors
InvestorRounds
Long Island High Technology IncubatorAccelerator
Food and Drug AdministrationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 29, 2026

    Grew 25% QoQ, from 12 to 15 employees.

  • Aug 2, 2026

    Grew 27% QoQ from 11 to 14 employees.

iCell Gene Therapeutics Filings

Explore SEC and related filing metadata, where available.

iCell Gene Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about iCell Gene Therapeutics's valuation, stock price, and market status.

Is iCell Gene Therapeutics a public or private company?

iCell Gene Therapeutics is a private company.

What is the current stock price of iCell Gene Therapeutics?

iCell Gene Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is iCell Gene Therapeutics worth (valuation)?

Valuation information for iCell Gene Therapeutics is not publicly available.

Can I buy iCell Gene Therapeutics stock?

iCell Gene Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was iCell Gene Therapeutics's last funding round?

iCell Gene Therapeutics's most recent funding round was Grant on October 8, 2020.

Who are the main investors in iCell Gene Therapeutics?

Key investors in iCell Gene Therapeutics include Long Island High Technology Incubator, Food and Drug Administration.

Will iCell Gene Therapeutics IPO soon?

No public IPO plans have been announced for iCell Gene Therapeutics.

How can I track iCell Gene Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor iCell Gene Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersStony Brook, New York
Employee Range14
Year Founded2014
Last FundingOct 8, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?